Bleomycin에 의해 유도된 경화성 동물모델 및 켈로이드 섬유모세포에서 Silibinin의 항 섬유화 효과

Abstract

Background: Silibinin reduces the expression of Type I collagen in normal skin fibroblasts through down-regulation of the TGF-β/smad pathway. However, it is largely unknown whether silibinin can reduce the expression of Type I collagen in vivo sclerotic animal models, as well as in keloid fibroblasts. Objective: The purpose of this study was to investigate the effect of silibinin on the expressions of type I collagen, matrix metalloproteinase-1 (MMP-1), MMP-2, smad2/3, and TGF-b1 receptor in keloid fibroblasts in vitro, and to evaluate the anti-fibrotic effect of silibinin in a bleomycin-induced, scleroderma-like animal model in vivo. Methods: Keloid and normal skin fibroblasts were treated with silibinin (20∼100 mM), and the expressions of type I collagen, MMP-1, MMP-2, and TGF-b1 receptor were analyzed with western blot. The animal model was established by bleomycin treatment (1.0 mg/mL) for 2 weeks in C57/BL9 mice. Then silibinin was injected on one side of the back and the same volume of normal saline was injected on the other side of the back. The specimen was evaluated with H&E, Masson-trichrome, and TGF-β1 immunohistochemical staining. Results: Expressions of Type I collagen, MMP-1, and MMP-2 decreased, but the expression of TGF-β1 receptor increased in keloid fibroblasts after silibinin treatment. Thickened dermis with dense extracellular matrix and inflammatory cell infiltration of the bleomycin-induced, scleroderma-like animal model improved after silibinin treatment. Expression of TGF-β1 decreased after silibinin treatment in the bleomycin-induced, scleroderma-like animal model. Conclusion: Silibinin treatment decreased the expression of Type I collagen in keloid fibroblasts in vitro. In addition, silibinin decreased the expression of Type I collagen by inhibiting TGF-β1 expression in the bleomycininduced, scleroderma-like animal model. These results indicate that silibinin has the potential to be an effective antifibrotic agent.